218 related articles for article (PubMed ID: 11459199)
1. Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines.
Ling YH; Donato NJ; Perez-Soler R
Cancer Chemother Pharmacol; 2001 Jun; 47(6):473-80. PubMed ID: 11459199
[TBL] [Abstract][Full Text] [Related]
2. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
[TBL] [Abstract][Full Text] [Related]
3. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor.
Nishikawa K; Rosenblum MG; Newman RA; Pandita TK; Hittelman WN; Donato NJ
Cancer Res; 1992 Sep; 52(17):4758-65. PubMed ID: 1380890
[TBL] [Abstract][Full Text] [Related]
4. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.
Ishii M; Iwahana M; Mitsui I; Minami M; Imagawa S; Tohgo A; Ejima A
Anticancer Drugs; 2000 Jun; 11(5):353-62. PubMed ID: 10912951
[TBL] [Abstract][Full Text] [Related]
5. Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells.
Kiyozuka Y; Yamamoto D; Yang J; Uemura Y; Senzaki H; Adachi S; Tsubura A
Anticancer Res; 2000; 20(1A):203-12. PubMed ID: 10769656
[TBL] [Abstract][Full Text] [Related]
6. EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity.
Donato NJ; Perez M; Kang H; Siddik ZH; Ling YH; Perez-Soler R
Clin Cancer Res; 2000 Jan; 6(1):193-202. PubMed ID: 10656450
[TBL] [Abstract][Full Text] [Related]
7. Silencing of fused toes homolog enhances cisplatin sensitivity in cervical cancer cells by inhibiting epidermal growth factor receptor-mediated repair of DNA damage.
Subramanian PD; An Z; Yu JR; Park WY
Cancer Chemother Pharmacol; 2016 Oct; 78(4):753-62. PubMed ID: 27535835
[TBL] [Abstract][Full Text] [Related]
8. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
Erlichman C; Boerner SA; Hallgren CG; Spieker R; Wang XY; James CD; Scheffer GL; Maliepaard M; Ross DD; Bible KC; Kaufmann SH
Cancer Res; 2001 Jan; 61(2):739-48. PubMed ID: 11212277
[TBL] [Abstract][Full Text] [Related]
9. Optimal combination chemotherapy and chemoradiotherapy with etoposide for advanced cervical squamous cancer cells in vitro.
Tanaka T; Bai T; Yukawa K; Umesaki N
Oncol Rep; 2006 Apr; 15(4):939-47. PubMed ID: 16525683
[TBL] [Abstract][Full Text] [Related]
10. Demethylation restores SN38 sensitivity in cells with acquired resistance to SN38 derived from human cervical squamous cancer cells.
Tanaka T; Bai T; Toujima S; Utsunomiya T; Matsuoka T; Kobayashi A; Yamamoto M; Sasaki N; Tanizaki Y; Utsunomiya H; Tanaka J; Yukawa K
Oncol Rep; 2012 Apr; 27(4):1292-8. PubMed ID: 22246465
[TBL] [Abstract][Full Text] [Related]
11. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.
Janss AJ; Cnaan A; Zhao H; Shpilsky A; Levow C; Sutton L; Phillips PC
Anticancer Drugs; 1998 Aug; 9(7):641-52. PubMed ID: 9773809
[TBL] [Abstract][Full Text] [Related]
12. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
Jensen PB; Holm B; Sorensen M; Christensen IJ; Sehested M
Br J Cancer; 1997; 75(6):869-77. PubMed ID: 9062409
[TBL] [Abstract][Full Text] [Related]
13. EGFR inhibitor enhances cisplatin sensitivity of oral squamous cell carcinoma cell lines.
Hiraishi Y; Wada T; Nakatani K; Tojyo I; Matsumoto T; Kiga N; Negoro K; Fujita S
Pathol Oncol Res; 2008 Mar; 14(1):39-43. PubMed ID: 18347929
[TBL] [Abstract][Full Text] [Related]
14. A novel mechanism for acquired cisplatin-resistance: suppressed translation of death-associated protein kinase mRNA is insensitive to 5-aza-2'-deoxycitidine and trichostatin in cisplatin-resistant cervical squamous cancer cells.
Bai T; Tanaka T; Yukawa K; Umesaki N
Int J Oncol; 2006 Feb; 28(2):497-508. PubMed ID: 16391806
[TBL] [Abstract][Full Text] [Related]
15. Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.
van Waardenburg RC; de Jong LA; van Eijndhoven MA; Verseyden C; Pluim D; Jansen LE; Bjornsti MA; Schellens JH
J Biol Chem; 2004 Dec; 279(52):54502-9. PubMed ID: 15471886
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.
Chen Y; Ke G; Han D; Liang S; Yang G; Wu X
Exp Cell Res; 2014 Jan; 320(1):12-20. PubMed ID: 24183997
[TBL] [Abstract][Full Text] [Related]
17. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines.
Keshelava N; Groshen S; Reynolds CP
Cancer Chemother Pharmacol; 2000; 45(1):1-8. PubMed ID: 10647494
[TBL] [Abstract][Full Text] [Related]
18. Profile of epidermal growth factor receptor (EGFr) expression in human malignancies: effects of exposure to EGF and its biological influence on established human tumour cell lines.
Nouri AM; Thompson C; Cannell H; Symes M; Purkiss S; Amirghofran Z
Int J Mol Med; 2000 Oct; 6(4):495-500. PubMed ID: 10998445
[TBL] [Abstract][Full Text] [Related]
19. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
[TBL] [Abstract][Full Text] [Related]
20. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]